系统性硬化症和形状性硬化症治疗的最新进展
1Department of Dermatology, Oregon Health and Science University, 3303 SW Bond Avenue, Portland, OR, 97239, USA.
American journal of clinical dermatology
|December 12, 2023
概括
系统性硬化症 (SSc) 和形态性硬化症是共享血管问题和TGFβ参与的自身免疫性疾病. 通过向这些已知的致病途径以获得更好的结果,治疗方法正在进步.
科学领域:
- 风湿病学和免疫学
背景情况:
- 系统性硬化症 (SSc) 和形态性硬化症是具有显著发病率和死亡率的自身免疫性硬化疾病.
- 这两种疾病都有共同的致病途径,包括血管功能障碍,自动反应性T细胞,Th2-关联细胞因子 (如白蛋白-4),以及转化生长因子β (TGFβ) 的过度生产.
研究的目的:
- 审查最近在治疗Morphea,SSc中的皮肤硬化症和SSc中的间歇性肺病方面的进展.
- 突出了针对这些不同但相关疾病的已知致病途径的重点.
主要方法:
- 关于SSc和morphea的病变和治疗的当前文献的审查.
- 分析它们疾病途径中的共同和独特特征.
- 检查针对特定分子通路的近期治疗进展.
主要成果:
- 确定了共享的致病机制,包括血管功能障碍,T细胞参与和TGFβ信号传递.
- 证实尽管有共同的途径,但morphea和SSc是不同的疾病.
- 突出了针对这些途径的近期治疗进展,用于形,SSc皮肤硬化和SSc相关的间歇性肺病.
结论:
- 针对TGFβ信号传递等共享的致病途径,为Morphea和SSc.提供了有前途的治疗策略.
- 对这些途径的持续研究对于开发对这些衰弱的自身免疫性疾病更有效的治疗方法至关重要.
更多相关视频
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
2.4K
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.1K
相关概念视频
iPS Cell Differentiation
2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
